`Atezolizumab` plus `Avastin` Significantly Improves Progression Free Survival Compared with Sunitinib in PD-L1 Positive Patients for the First-line Treatment of Advanced Renal Cell Carcinoma in the IMmotion151 Study
(WorldNews Japan)

TOKYO, December 11, 2017 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that the phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression free survival (PFS), and demonstrated that the combination of atezolizumab and Avastin®showed statistically significant improvement in PFS compared with sunitinib in patients whose disease expressed PD-L1 (programmed death-ligand 1: Expression